No association found between thiazolidinediones and bladder cancer

the ONA take:

According to a new study published in the journal Diabetologia, there is no link between either pioglitazone or rosiglitazone and bladder cancer.

For the study, the researchers collected prescription, cancer, and mortality data from 1.01 million people with type 2 diabetes from six populations in Europe and North America. Of those, 3,248 developed bladder cancer and only 117 of those were in patients who had taken pioglitazone. 

Results showed that there was no link between cumulative exposure to the thiazolidinediones and bladder cancer in men or women after adjustment for other factors. In addition, longer exposure to pioglitazone did no increase the risk for developing bladder cancer.

According to the American Cancer Society, there will be an estimated nearly 75,000 new cases of bladder cancer and about 15,600 deaths from the disease. Men are about 3 to 4 times more likely to develop bladder cancer than women, but that risk is about 1 in 26 men.

Previous studies have shown that drugs from this class of antidiabetic drugs increases the risk of bladder cancer, but this study demonstrates otherwise. The authors suggest that studies with a longer duration of follow-up of patients exposed to pioglitazone or rosiglitazone be conducted to end the controversy.

A new target for aggressive bladder cancer found
There is no link between either pioglitazone or rosiglitazone and bladder cancer.
Some previous studies have linked the diabetes medication pioglitazone to bladder cancer. They are used in the treatment of type 2 diabetes, however their use, has been questioned owing to safety concerns, including preclinical studies showing male rats overexposed to pioglitazone were at increased risk of bladder cancer.
READ FULL ARTICLE From Medical News Today
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs